When you expertise abnormal drowsiness often, perhaps after you have only had a good evening sleep. Quite often you fall napping actually for those who do not want that, and you do that on situations exactly where you cannot control it. Often you collapse or your muscle destroy, specifically for those who have only had some powerful emotions, tension, hate, laughter or some other feelings. Once you fall sleeping or get up you cannot move for quite a few time and are not capable to talk or move.

You can find remedies which are readily available to deal with signs or symptoms of narcolepsy disease, like Generic provigil (modalert), and so see a physician for an guide.

Provigil medication has been classified as a category C medicine within the Usa, which indicates that there happen to have been no tests done on people to understand what effects it has on unborn infants. It has moreover not been researched whether or not Provigil Generic has an ability to pass into the breast milk, but considering that virtually all medicines do it’s fair to presume that Provigil would have the similar way of actioning.

Therfore before you commence taking this treatments discuss all pros and contras with your doctor. Don’t stop using Provigil drug without consulting with a health care provider.

We as a society has moved in to a 24 hour cycle, sometimes confused when we need to sleep and have rest. We experience a lot of pressure to stay awake for longer hours, or to do longer shifts.

There have been a number of research done, which have shown that people doing night shifts, have difficulty to fall asleep during day time, theit performance is reduced and they find difficult to stay focused and alerted when it’s needed. They also have a higher accident rate, comparing to people doing  nine to five jobs.

Another issue is the general health. The shift workers are more likely to develop such diseases as sleep disorders of all kind, risks of having cardiovascular disease, diabetes and others.

In addition to that the accidents caused by sleepiness cost the economy a lot of money.

While patients report excessive daytime sleepiness and cataplexy as the more frequent symptoms of this condition, excessive daytime sleepiness is generally believed to be the most debilitating.

Narcolepsy often is undiagnosed or misdiagnosed for a variety of reasons. Although confirmation of an initial diagnosis requires monitoring of physiologic variables conducted at a sleep center by specialists, the primary care physician has a critical role in the identification and management of this incurable affliction.

This article provides recommendations for the diagnosis and management of narcolepsy. The cataplexy associated with narcolepsy can be managed with tricyclic antidepressants.

The excessive sleepiness is managed with stimulants but newer agents, such as Provigil, which will be marketed as Provigil, and selegiline hydrochloride, with fewer adverse effects and less abuse potential, may offer means of promoting daytime wakefulness.

Groups such as the National Sleep Foundation, Washington, DC, and the Narcolepsy Network, Cincinnati, Ohio, can provide patients with needed support and information.

The aim of the study is to compare the effects of single doses of Provigil and clonidine on arousal and autonomic functions in human volunteers.

Sixteen healthy male volunteers participated in four experimental sessions (modafinil 200 mg; clonidine 0.2 mg; modafinil 200 mg + clonidine 0.2 mg; placebo) at weekly intervals, according to a balanced double-blind protocol. Arousal [pupillary "fatigue waves" (PFW), critical flicker fusion frequency, self-ratings of alertness] and autonomic functions (pupil diameter, pupillary light and darkness reflex responses, blood pressure, heart rate, salivation) were recorded. Data were analyzed with ANOVA, with multiple comparisons.

Clonidine reduced subjective alertness, pupil diameter, the initial velocity and amplitude of the darkness reflex response, systolic and diastolic blood pressure and salivation, prolonged the recovery time of the light reflex response and increased PFW. Provigil reduced PFW, increased pupil diameter and the initial velocity of the darkness reflex response and tended to reduce the effect of clonidine on pupil diameter and PFW. Modafinil had no effect on non-pupillary autonomic functions.

Clonidine exerted sympatholytic and sedative effects, whereas modafinil had sympathomimetic and some alerting effects. Provigil may activate noradrenergic neurones in the LC involved in arousal and pupillary control, without affecting extracoerulear noradrenergic neurones involved in cardiovascular and salivary regulation.

Warnings and precautions also extend to people who are allergic to any components of the medication.

Provigil: What Should I Tell My Healthcare Provider?

• Liver disease, such as liver failure, cirrhosis, or hepatitis
• Kidney disease, including kidney failure (renal failure)
• Any heart condition or problem
• High blood pressure (hypertension)
• Any allergies, including allergies to food, dyes, or preservatives.

• Pregnant or thinking of becoming pregnant
• Breastfeeding.

• In rare cases, Provigil can cause a life-threatening side effect known as Stevens-Johnson syndrome. Because this problem starts out with a rash, contact your healthcare provider immediately if you develop any unexplained rash while taking the drug. Because it is impossible to know if the rash will develop into Stevens-Johnson syndrome, your healthcare provider may recommend that you stop taking Provigil.
• The medication can cause severe allergic reactions. Seek medical attention immediately if you develop signs of an allergic reaction, such as hives, itching, wheezing or difficulty breathing, or swelling of the lips, mouth, or throat.
• Even though Provigil helps people stay awake, it usually is not completely effective at eliminating sleepiness. This can cause problems while driving or operating heavy machinery.
• Provigil is a controlled substance, which means that it has the potential to be abused. If you feel the need to take more of the drug than prescribed or for a non-medical reason, please discuss this with your healthcare provider honestly and openly. These may be signs that you might have a problem with Provigil abuse or dependence.
• Some people have experienced psychiatric symptoms (such as anxiety, depression, hallucinations, or suicidal thoughts) while taking Provigil. Be sure to watch for these side effects. It may be wise to ask someone you trust to watch you carefully for such symptoms, as you may not notice them yourself.
• You should have an accurate and definite diagnosis of narcolepsy, obstructive sleep apnea, or shift worker sleep disorder before taking Provigil. Many other conditions and sleep disorders can cause excessive sleepiness, so tests may be necessary in order to accurately diagnose your condition.
• When given to people with obstructive sleep apnea, Provigil should not be used without appropriate sleep apnea treatment (such as continuous positive airway pressure or CPAP). Provigil only improves daytime sleepiness; it has no effect on the actual sleep apnea.
• The medication may not be safe for people with heart problems or high blood pressure. If you have such problems, check with your healthcare provider before taking Provigil.
• Provigil can interact with a number of different medications (see Provigil Drug Interactions). It is important to note that the medication can decrease the effectiveness of birth control pills, patches, and rings, possibly increasing the risk of pregnancy.
• If you have kidney or liver problems, your body may not handle Provigil as well as it should. You may need a lower dosage and, in some cases, the drug may not be recommended.
• It is not known if it is safe to drink alcohol while taking Provigil. Until more information is available, you should avoid alcohol (or at least limit your alcohol intake) while taking the drug.
• Provigil is considered a pregnancy Category C medication. This means that it may not be safe for use during pregnancy, although the full risks are not known (see Provigil and Pregnancy).
• It is not known if Provigil passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking the drug (see Provigil and Breastfeeding). It is important to understand that the HIV virus can be transmitted through breast milk and that breastfeeding is usually not recommended in women with HIV or AIDS.

Who Should Not Take Provigil?

As with any medicine, side effects are possible with Provigil® (modafinil); however, not everyone who takes the drug will experience side effects. In fact, most people tolerate it quite well. If side effects do occur, in most cases, they are minor and either require no treatment or can easily be treated by you or your healthcare provider.

Common Side Effects of Provigil

Provigil has been studied thoroughly in clinical trials. In these studies, the side effects that occur in a group of people taking the drug are documented and compared to side effects that occur in another group of people not taking the medicine. This way, it is possible to see what side effects occur, how often they appear, and how they compare to the group not taking the medicine.

In these studies, the most common side effects with Provigil included:

• Headaches — in up to 34 percent of people
• Nausea — up to 11 percent
• Nervousness — up to 7 percent
• Runny or stuffy nose — up to 7 percent
• Back pain — up to 6 percent
• Diarrhea — up to 6 percent
• Indigestion or heartburn — up to 5 percent
• Insomnia — up to 5 percent (see Provigil and Insomnia)
• Dizziness — up to 5 percent.

Other common Provigil side effects, occurring in 1 to 4 percent of people, included:

• Flu-like symptoms (such as fever and chills)
• Dry mouth (see Provigil and Dry Mouth)
• Loss of appetite
• Sore throat
• Flushing or hot flashes
• Constipation
• Unusual sensations, such as numbness or tingling
• Drowsiness

Provigil and Rashes

Like many other medications, Provigil can cause a rare, extremely dangerous side effect called Stevens-Johnson syndrome (SJS). This problem starts out as a rash, but it can soon become life-threatening, sometimes resulting in the loss of large segments of skin (which can lead to disfigurement or even death). Therefore, tell your healthcare provider immediately if you develop an unexplained rash while taking the drug. In almost all cases, Provigil should be stopped, since it is impossible to tell if any particular rash will become dangerous. If you cannot reach your healthcare provider immediately, you should stop taking Provigil until you receive further instructions.

Final Thoughts

You may experience some or none of the Provigil side effects listed in this article. Unfortunately, it can be difficult to tell whether any particular side effect (such as nausea) is actually caused by Provigil or other factors. Therefore, make sure to let your healthcare provider know if you develop any side effects while taking the drug or if something “just does not seem right.” While you may not be experiencing a side effect, your healthcare provider will be able to diagnose and treat the problem.

http://sleep.emedtv.com/provigil/provigil-side-effects-p2.html

Several headline catastrophes such as the Challenger explosion, the Bhopal disaster, the Exxon Valdez oil spill, the Three Mile Island and the Chernobyl reactor meltdown have been, at least in part, attributed to human errors secondary to fatigue and sleepiness, which might have been related to the effects of shiftwork.

Exposure to shiftwork is associated with increased sick leave and increased prevalence of various somatic conditions, including coronary heart disease and peptic ulcer. Disruption of the circadian rhythm leads to hormonal changes; therefore, women working night shifts are more prone to developing menstrual irregularities, infertility and adverse pregnancy outcomes.

Sleep disorders are not restricted to night hours but they have a profound effect on our everyday daytime functioning, productivity, home, travel and workplace safety, mental and physical wellbeing and QoL. This review only covered the most common sleep disorders (i.e., insomnia, RLS, OSAS and shiftwork-related sleep disorder), but we must acknowledge that there is a large variety of less common sleep disorders that also have deleterious effects on the overall wellbeing and QoL of the individuals affected.

Shiftwork can be defined as “a way of organizing daily working hours in which different persons or teams work in succession to cover more than the usual 8-h workday, up to and including the whole 24 h”. In practical terms, any work schedule is considered shiftwork if they are not within the 09:00-17:00 or 08:00-16:00 time range.

Continuous measures of electroencephalogram (EEG) sleep-wakefulness, locomotor activity (LMA) and body temperature (Tb) were obtained from adult male Wistar rats 3 days before and after treatment with Provigil (30, 100 and 300 mg/kg i.p.), 0.25% methylcellulose (vehicle) or METH (0.5 and 1.0 mg/kg i.p.). Individually housed rats in a 24-h light-dark cycle (LD 12:12) were treated 5 h after lights-on (CT-5).

LMA and Tb were monitored via intraperitoneal telemetry. Sleep-wake stages and LMA were recorded every 10 s, Tb every minute. During the first 3 h post-treatment, Provigil and METH significantly and dose-dependently increased EEG wake time (P < .01 for 30 mg/kg Provigil, all other P < .0001) and wake episode duration.

Although the cumulative increases in wakefulness were statistically equivalent, METH, but not Provigil, produced subsequent rebound hypersomnolence.

At these equipotent wake-promoting doses, Provigil produced the same total amount of REM sleep inhibition but during a longer time than METH. Provigil also increased LMA amount (counts/h, P < .001) and LMA intensity (counts/min awake, P < .001) less than METH. Both rebound hypersomnolence and increased LMA intensity, which are undesirable features in wake-promoting drugs, were not observed after Provigil treatment, and thus further differentiated Provigil from amphetamine-like stimulants.

Their judgment was impaired, he claimed, because superiors pressured them to prepare for the mission by taking Dexedrine, a practice he described as common. The charges were dropped, but not before the revelation sparked public outrage: Why were our boys flying $30 million jets on uppers?

That the pilots were using chemicals to remain alert shouldn’t have surprised anyone: Officers have always sought ways to keep the troops awake. Chinese sentries along the Great Wall took the herb ma huang (active ingredient: ephedrine). Incan warriors chewed coca leaves in Andean passes. And the Air Force itself has used “go pills” since World War II. Today, a program funded by Darpa is studying natural alertness mechanisms like that of the white crowned sparrow, which can stay awake for up to two weeks during migration. The goal is to produce a GI who can go without sleep for seven days.

Right now, the US Army Aeromedical Research Laboratory is testing an antisleep agent called Provigil. Developed by the French firm Lafon to fight narcolepsy and sold by Pennsylvania drugmaker Cephalon under the name Provigil, the compound can keep users up for two or three days at a stretch, with negligible side effects and little risk of addiction. Provigil was approved by the FDA in 1998 and has been used to treat excessive sleepiness in patients with Parkinson’s, Alzheimer’s, and multiple sclerosis; it’s also been shown to help cocaine addicts kick the habit. The French Foreign Legion used the drug in Gulf War I, and although the Pentagon won’t comment, several news outlets reported that coalition troops were taking it during the drive to Baghdad earlier this year.

But Provigil isn’t just for soldiers and sick people anymore. This year, Cephalon submitted to the FDA a supplemental application that would give physicians a free hand to prescribe Provigil for lesser sleep problems, such as shift-work drowsiness. Even without that approval, the drug is attracting a wider market: Truckers, students, and others pulling all-nighters account for a growing portion of Provigil’s $200 million in annual sales.

In the mainstream media, the discovery of a chemical key to a 24/7 society sparked the predictable hand-wringing. But Provigil has little appeal as a recreational drug. Unlike amphetamines, which stimulate the entire central nervous system, Provigil doesn’t jazz up users – it simply shuts off their sleep jones. There’s none of the euphoria produced by cocaine or the bliss from ecstasy. It just helps people stay awake. And eventually, staying awake just gets boring.

In fact, the medical establishment is excited about Provigil precisely because it’s the first effective stimulant with no significant potential for abuse. What’s more, the same research that led to stay-awake drugs will revolutionize treatment of a sleep disorder at the opposite end of the spectrum: insomnia. During the past decade, scientists have realized that the urges for sleep and wakefulness aren’t subject to a single control like the throttle of a boat. Rather, they’re interrelated yet independent drives controlled by distinct mechanisms in the brain – think of the accelerator and brake in a car. Scientifically, Provigil’s beauty is in its precision. Although its exact mechanism of action is not fully understood, it affects only the urge to stay awake.

That same basic breakthrough behind Provigil is already being used by several companies – Cephalon, Neurocrine Biosciences, and an innovator in the field, Hypnion – to develop compounds similar to but more effective than Provigil. Within a decade, some say, continuous alertness could be available over the counter. And since the technique of targeting a specific receptor will likely lead to better sleeping pills, a restful night could be sold in drugstores as well; chronic insomnia, a condition that affects 20 to 40 percent of Americans, could be a thing of the past.

“It’s time for a revolution,” says Dale Edgar, cofounder of Hypnion. He should know – he’s the scientist whose research on sleep helped lay the groundwork for Provigil. “The drugs will do for sleep disorders what Prozac did for depression.”

In a technology park in Worcester, Massachusetts, down hallways bathed in muted red light, live the best-rested rodents in the world. As researchers in surgical gear tiptoe past their cages, dozens of mice and rats doze contentedly; others scurry around their Plexiglas enclosures. Affixed to each of them are miniature radio transmitters.

These animals are the test subjects for Hypnion’s new sleep-wake drugs. Company scientists monitor the results with a drug-testing system called Score 2000 that receives the radio signals and tracks reactions remotely over a network. In an adjoining lab, data streaks across terminals: vital signs, movement, feeding habits, and, most important, sleep patterns. Edgar developed the system with a colleague at Stanford using a grant from the Air Force and the Department of Defense, which was looking into applications of medical sensing for troops in the field.

Hypnion is so deep in stealth mode that some people in sleep science don’t even know it exists. Edgar, however, has already made his mark: In the mid-’90s, under contract for Cephalon, he used an earlier version of Score to help perfect Provigil and make the Pennsylvania firm one of the hottest in the biotech world.

Now Edgar and his team are developing a line of anti-drowsiness pharmaceuticals that they hope will put Hypnion in the same league. While Provigil represents a breakthrough, he says, “the first drug in its class is rarely the best.” As a private company in preclinical development, Hypnion won’t say much about what it has in the pipeline, but just as Prozac has largely been superseded by Zoloft and Paxil, Edgar believes Provigil will be replaced by better wakefulness drugs.

Despite Edgar’s research, though, most scientists in the field clung to the notion that sleepiness was a single cause-and-effect mechanism, rather than a sum of two separate urges. “I went from university to university giving lectures” Edgar recalls, “basically being a lobbyist.” He gradually won over the doubters and published his findings in the Journal of Neurobiology in 1993.

Three years ago, Edgar and a colleague, Emmanuel Mignot, left Stanford to found Hypnion. He packed up his family in Palo Alto and drove across the country into Massachusetts and the unknown. “I was scared to death,” he admits now. “I’m a third-generation Californian, and I had a tenured position. Here I was moving cross-country to start something that might fail.”

Anti-sleep drugs may grab the headlines, but tranquilizers – called hypnotics by sleep docs – will eventually help millions more people. The market for sleeping pills is substantially larger than for Provigil-style wakefulness promoters – an estimated $1.5 billion in the US alone. That’s why Hypnion is going after the ideal insomnia fighter first.

Over the years, the search for perfect tranquilizers has led down byways of addiction and overdose. In the 1970s, barbiturates, which are particularly dangerous, were replaced by benzodiazepines like Librium and Valium. But so-called BZDs became known for their side effects: memory loss, rebound insomnia, dependence, withdrawal, and sometimes seizures, paranoia, and depression. Today’s leading insomnia medication, Ambien (zolpidem), isn’t technically a BZD, but it works on the same neural pathway, suppressing activity across the brain.earching for a truly novel drug, and armed with $10.4 million in seed money from investors led by Boston VC firm Oxford Bioscience Partners, Hypnion is examining the brain’s sleep-wake pathways to determine which of them make good targets for new drugs. Medicinal chemist David Hangauer, a professor at SUNY Buffalo and an accomplished drug designer, took Hypnion’s specs and just “started making molecules,” according to Edgar. Using the information generated by Score 2000, Edgar’s team gradually whittled down the candidate compounds to a short list. Last March, the company secured $47.5 million more in funding from a group of investors led by Southern California-based Forward Ventures, enough to keep operations going for three years. By early 2004, its first anti-insomnia medication, dubbed HY2901, could be in Phase I trials.

“Before, you’d take a large number of molecules, do in vitro tests, and see how they behaved pharmacologically – what the side effects were,” says Edgar. “Now we’re building the molecules, so there are no side effects to begin with.” The result, he says, will be drugs with almost no potential for abuse or addiction. A competing medicine is already in trials: Japanese pharmco Takeda is testing Ramelteon, a substance designed to treat sleep transient and chronic insomnia, with the goal of helping people fall asleep faster. Hypnion is going after so-called sleep maintenance drugs that help people stay asleep – the problem for the majority of chronic insomniacs – as opposed to fall asleep. And since sleeping can be more difficult as people age, the market will grow as baby boomers get older.

Eventually, we could all be as well rested as Hypnion’s lab rodents, our sleep patterns precisely controlled. But even if science is ready for the new generation of sleep medications, society may not be. In August, US track star Kelli White tested positive for Provigil after winning two gold medals at the World Track and Field Championships. She was taking the drug to combat narcolepsy, but the IAAF, the sport’s governing body, classifies it as a stimulant and recommended she be stripped of her medals.